Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas
Por:
Sorigue, M and Kuittinen, O
Publicada:
1 ene 2023
Resumen:
Simple Summary Systemic peripheral T cell lymphomas (PTCL) are a rare and clinically and biologically heterogeneous group of disorders with scarce and generally low-quality evidence guiding their management. In this manuscript, we tackle the current controversies in the front-line treatment of systemic PTCL and give our thoughts vis-a-vis potential developments to come in the next few years. Systemic peripheral T cell lymphomas (PTCL) are a rare and clinically and biologically heterogeneous group of disorders with scarce and generally low-quality evidence guiding their management. In this manuscript, we tackle the current controversies in the front-line treatment of systemic PTCL including (1) whether CNS prophylaxis should be administered; (2) whether CHOEP should be preferred over CHOP; (3) what role brentuximab vedotin should have; (4) whether stem cell transplant (SCT) consolidation should be used and whether autologous or allogeneic; (5) how should molecular subtypes (including DUSP22 or TP63-rearranged ALCL or GATA3 or TBX21 PTCL, NOS) impact therapeutic decisions; and (6) whether there is a role for targeted agents beyond brentuximab vedotin.
Filiaciones:
:
UAB, Hosp Germans Trias & Pujol, ICO IJC, LUMN,Dept Hematol, Badalona 08916, Spain
Kuittinen, O:
Univ Eastern Finland, Inst Clin Med, Fac Hlth Med, Kuopio 70211, Finland
Oulu Univ Hosp, Med Res Ctr & Canc, Oulu 90220, Finland
Oulu Univ Hosp, Canc & Translat Res Unit, Oulu 90220, Finland
Univ Oulu, Oulu 90220, Finland
Kuopio Univ Hosp, Dept Oncol, Kuopio 70210, Finland
Green Published, gold
|